Kodiak Sciences Inc.
No enriched coverage for $KOD in the last 7 days.
No SEC Form 4 filings for $KOD in the last 30 days.
See all $KOD insider activity →Kodal Minerals (AIM: KOD) reported Bougouni lithium project results for the quarter ended 30 June 2026. Spodumene concentrate output was 26,174 DMT at 5.34% Li2O, with 53,195 DMT year to date. A US$13m initial repayment was made by operator LMLB to KMUK. Third shipment (~20,400 DMT) arrived in Hainan; interim payment was $34.4m for 95% of estimated value.
MarketBeat reports that eight brokerages covering Kodiak Sciences (NASDAQ:KOD) give an average “Moderate Buy” rating, with one sell, one hold, and six buy ratings. The average 1-year price target is $42.14. UBS raised its target to $80; HC Wainwright set $58; Chardan lifted to $61. KOD shares opened at $32.94 and last reported EPS of ($0.94) for May 7, slightly below consensus.
Kodiak Sciences CFO John A. Borgeson sold 30,000 shares on June 4, 2026 via option exercise and immediate open-market sale, according to an SEC Form 4. The weighted average purchase price was $34.10. His direct holdings fell 12.40% to 211,930 shares, leaving about $7.24 million in direct common stock value. The sale followed a 10b5-1 plan.
Recent KOD coverage spans financial news and insider activity.
Operational execution and cashflow timing are the key drivers: crushing/DMS issues in May, improved June throughput, and interim shipment payments.
Street target revisions are supportive for sentiment, but the piece is still an analyst-summary with no new clinical/regulatory catalyst.
Insider selling is disclosed as routine 10b5-1 liquidity, but it can still affect near-term sentiment after a sharp run-up.
Insider selling under a 10b5-1 plan is typically not a strong fundamental signal, but it can modestly affect near-term sentiment/positioning.
Insider selling disclosed on SEC Form 4; likely low fundamental signal given stated 10b5-1 pre-arranged plan.
alphai scores every news story that mentions KOD with an AI model for sentiment and relevance, and aggregates insider trades from Kodiak Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kodal Minerals (AIM: KOD) reported Bougouni lithium project results for the quarter ended 30 June 2026. Spodumene concentrate output was 26,174 DMT at 5.34% Li2O, with 53,195 DMT year to date. A US$13m initial repayment was made by operator LMLB to KMUK. Third shipment (~20,400 DMT) arrived in Hainan; interim payment was $34.4m for 95% of estimated value.
4 min readMarketBeat reports that eight brokerages covering Kodiak Sciences (NASDAQ:KOD) give an average “Moderate Buy” rating, with one sell, one hold, and six buy ratings. The average 1-year price target is $42.14. UBS raised its target to $80; HC Wainwright set $58; Chardan lifted to $61. KOD shares opened at $32.94 and last reported EPS of ($0.94) for May 7, slightly below consensus.
3 min readKodiak Sciences CFO John A. Borgeson sold 30,000 shares on June 4, 2026 via option exercise and immediate open-market sale, according to an SEC Form 4. The weighted average purchase price was $34.10. His direct holdings fell 12.40% to 211,930 shares, leaving about $7.24 million in direct common stock value. The sale followed a 10b5-1 plan.
4 min readBORGESON JOHN A. (Chief Financial Officer) sold 4,104 shares of Kodiak Sciences Inc. (KOD) at $34.67 ($0.14M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readBORGESON JOHN A. (Chief Financial Officer) sold 25,896 shares of Kodiak Sciences Inc. (KOD) at $34.01 ($0.88M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readKodiak Sciences Inc. announced positive results from its GLOW2 Phase 3 study of Zenkuda (tarcocimab tedromer) for treating diabetic retinopathy, leading to a significant increase in its stock price. The study met its primary endpoint, showing substantial improvement in diabetic retinopathy severity and an 85% risk reduction in sight-threatening complications. The company plans to expedite its Biologics License Application submission based on these findings, although InvestingPro analysis suggests the stock is currently overvalued.
4 min readBros. Advisors Lp Baker purchased 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD) stock on December 18th for $60 million, increasing their stake to over 18 million shares. This comes as Kodiak Sciences' shares dropped 1.4% on heavy trading volume, and the company missed its quarterly EPS estimates, with analysts projecting a full-year EPS of -3.45. Despite a mixed analyst outlook, the firm has an average "Hold" rating and a consensus target price of $22.67.
4 min readKOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
3 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
3 min readU.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Thursday. Shares of Ameresco, Inc. ( NYSE: AMRC ) rose sharply during Thursday's session after Jefferies upgraded the stock from Hold to Buy and raised its price target from $19 to $39.
3 min read
